Given this high response rate to single agent therapy, venetoclax has been used off-label for the treatment of r/r MCL, although as the MCL patients treated in the phase 1 study had not received prior BTKi treatment, data regarding the efficacy of venetoclax sequenced following BTKi treatment are currently limited to retrospective reports. Here, IBTK is linked to mantle cell lymphoma.